Clinical Trial Update: Capecitabine in Low Risk Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating capecitabine for low-risk triple-negative breast cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING